At this time, all participants are in listen-only mode. Before we begin the formal presentation, I'd like to remind everyone of several important things. Today's webinar is being recorded. A question and answer session will follow the formal presentation, so if you have questions during the presentation, you can type them into the Q&A chat to be answered during the Q&A session. Questions can only be seen by the moderator. Please remember that statements made on this webinar may contain provisions, estimates, or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risk and uncertainties that could cause actual results to differ materially. You're cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation.
Please be aware that we are not obligating ourselves to revise or publicly release results or any revision to these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions. You should also review our most recent Form 10-Q for a more complete discussion of these factors and other risks, particularly under the heading of risk factors. A press release detailing these results, which crossed the wire this afternoon, is available in the investor relations section of our website, mdb.com. A replay of this call will also be provided later on on mdb.com. Your host today is Chris Marlett, Chief Executive Officer and Co-Founder of MDB Capital Holdings. He'll be joined later by George Brandon, MDB President and Head of Community Development.
Chris will lead a business update for the quarter ending September 30, 2026, and subsequent developments. At this time, I'd like to turn the call over to Chris Marlett.
All right. Thanks, Tony. Well, thanks everyone for joining today. I know the market's been a bit tumultuous and a lot of uncertainty out there, and I appreciate you all taking the time today to join us for this call, and I'll get right into the update. I'm going to be decidedly upbeat, because I really believe that what we set out to do when we started MDB and took it public was to generate big ideas. Our whole history has been based on creating new enterprises and giving these big ideas access to public liquidity. Albeit the markets have not been super hospitable to small companies, we have no control over that, but we do have control over what we do.
Many of the companies or most of the companies in our history, we would look at these IP-centric companies that we believe have a real moat around them. We have also launched some other companies that we believe are transformative that were part of our platform, which we have talked a bit about historically, which is our self-clearing broker-dealer platform and our IP law firm, which we are very proud of. We created this structure of an LLC so that we could distribute out assets, and that is exactly what we still intend to do, is distribute these assets as soon as these companies hit an inflection point. We think that some of these companies are very near an inflection point, and why we are hopeful to be distributing out these assets very soon. We have executed on those ideas.
We have not executed on launching more companies purely because of the backdrop of the current market. When you look at, as we say, constrained access to capital and depressed valuations, we were hoping to launch two to three or four big ideas a year, which has just not been feasible in this market environment. But with the companies we have launched, we are very proud of them, and those companies have executed on their mission to get to commercialization and close to a big inflection point. Our road ahead right now with the market backdrop is to really make sure that the four key assets we have get to a value inflection point.
As we have talked about historically, it is Public Ventures, our clearing platform, PatentVest, our disruptive new age IP law firm, eXoZymes, which is, we believe, the leader in cell-free synthetic biology, which we think is going to be a huge market, and Paulex, folks that we have built a company with before that disrupted diabetes, and we believe this next drug or platform will disrupt diabetes again. Our core objective with all these assets has been to bring them to a value inflection point, and we are putting most of our efforts in helping those companies to get there at this time. We really need to see these companies perform, and we are very excited about where they sit today and their ability to impact the markets that they are going to be serving. We are going to be leaning up.
We are not blind to the market environment, so we need to run a much leaner shop, and we will be cutting expenses while we are also liberating ourself of current cash OPEX by funding and partnering Public Ventures and PatentVest going forward. We believe significant value has been built, and our teams have done magnificent work. They really have executed on standing up these companies and getting them close to commercialization. Our job is really to help each one of these companies get to that value inflection point as soon as humanly possible. Going to all four of those, the various opportunities, talk about why we did it, what we have accomplished, and what we see as the road ahead. Public Ventures was a super simple concept.
All of these companies that finance young micro-cap or small-cap companies had been challenged in the fact that clearing firms really didn't want to support these type of firms anymore. We saw there was a huge opportunity to serve this marketplace. Obviously, most of the investor capital has been going upmarket into very large companies, and now the market has largely been dominated by these companies. A lot of them, they're serving the AI marketplace, and the small companies have just been sort of forgotten for the most part. We don't think that's sustainable. We think ultimately money will rotate back into this asset class, and we've always believed that you need to have a purpose-built clearing firm to serve that marketplace. We feel the exact same today as we did when we started it, but we've actually executed on getting it stood up.
We also see that digital is going to become a very big part of it, whether that's tokenization or crypto-related assets. We do believe that investors are looking for different ways to invest in these companies, and it's also a globalization situation. We have so many foreigners investing in the U.S. capital markets today, and increasingly they're looking for easier ways to do that, whether that's through tokenized securities or other platforms that enable a lot less friction investing in these kind of companies. We have the ability to do that and serve the, let's call it this, the micro-caps or small-cap marketplace. We don't think it's easy to copy. We think that our intellectual capital that we have in this marketplace is significant.
We've been doing this for 30 years in this marketplace, and in fact, we have tremendous experience in doing this that nobody else has really. There's very few other firms that have as much experience in this sector as we do. Getting a clearing license takes years to earn and actually get it operational, and our firm's done that very cost-effectively and very efficiently. We began this sort of, I would say, almost five-year journey to actually get this thing stood up to where we could start clearing offerings. For those of you that have used MDB Direct and actually participated in the offerings, you see it works great. We built a great, solid technical platform, but now it's time for it to expand its capabilities. There are many ways that clearing firms make money, whether it's stock loan, margin, and more active trading.
Most of our accounts are not big-time active traders. We are in the discussions with numerous folks that are looking to have a clearing platform and utilize the strength of what we've built and our knowledge in this marketplace, as well as taking advantage of our trained team in Latin America, where we can operate not only with higher quality, and those of you that have had a chance to deal with our operations team, you know that we have a very professional team that's doing a great job, and we can do that in a very cost-efficient way. It's very hard to build a clearing firm in New York City today, expensive rent, expensive people. It's not the place to build it. We think we've built something super valuable with Public Ventures, and we couldn't be more proud of what we've done.
Where it stands is that we really have something that is ready set for someone that has visions for building these big platforms. We've seen recently some firms transact, where we've seen companies like Kalshi just go and buy a brokerage firm to be able to do something similar to this. Well, it turns out there's only approximately 100 clearing broker-dealers in the U.S. As we know, it's not easy to get. I think that now we are at sort of this inflection point where we need to partner with someone to really bring scale to it. We've been in discussions with several highly qualified folks that understand how to scale clearing operations. They see the value in what we've created, and we hope to conclude a transaction that we think will help realize the value of Public Ventures going forward.
We really see this as the next evolution of how new enterprises will enter the market. Even though today it is not the asset class of choice, we believe that money will rotate back into this sector as small companies need access to capital, and we see the public markets as being a great place for that. PatentVest, we saw a distinctly huge opportunity. What we saw in the area of patent law when we were starting new companies, especially companies that needed to file 50 or 100 patents to put a moat around their technology platform, was it was not only very costly to do, but it was very difficult to do because no law firms really married business intelligence with IP law.
When Arizona opened the door to enable this to be run in a businesslike way, as opposed to thinking about IP as a legal process, we thought of it as a business process. We saw this as a huge opportunity, and the team led by Javier Chamorro has done a phenomenal job of standing up this law firm. We've brought on several lawyers, we've trained paralegals, we have an entire analyst team that provides that critical sort of associate layer, and now, of course, with AI, is going to be supercharging this effort. What happened in the middle of building this, the great news is we were building this to serve a $30 billion global market that we knew was not being served by law firms currently, and AI just dramatically sped up the disruption.
I don't think that IP law is going to look anything like it has for the last five years. It's going to be very, very different going forward. What we see is the key part of it is integrating business strategy, IP strategy, R&D, and have that in a really unified and connected way. I'm 100% confident no law firm has delivered upon that, and we are now ready to do that. What it took was training these analysts and paralegals and lawyers to work in this unified process, of course, organizing it under Arizona law. Our technology is, we took 30 defined processes that we were building historically in a digital place, but without AI. What happened with AI is it just supercharged the entire effort, and it dramatically lowered our technology development costs.
But we had all these defined processes that were put in place that enabled us to be super efficient, and now with AI, we are achieving things that have never been achieved before in the practice of IP law. We can take something from an invention, put it into business context, IP context, develop claims that can be granted by the patent office, examine those claims, and when we file it, we can literally have demonstrated we can do this in one day. This would take months before to happen. It is the most disruptive thing I've ever seen. When we've got a company like eXoZymes that needs to probably file 100 patent applications a year, there's no way that that could have been done both cost-effectively and efficiently in any kind of way.
We now have the ability to process 1,000 patent applications a year in a legally compliant manner, and legally compliant is really the most key aspect of what we're talking about, because you can't just put things into ChatGPT or Claude as an inventor or as a lawyer and effectively process that whole application to grant a patent in that way. Our team has put together an incredible platform that is legally compliant, and we are now rolling it out. Like I said, we can take an invention and put it into a legal and business context, instantly create those claims, give the company an R&D roadmap, and the efficiency and cost is something that's never been seen before.
I really do believe we have a real lead over other people, and that it will not become easily replicated because we were built to do it this way from the very beginning. Where it stands, the tech stack is built, the team is trained, and it's no longer just talk. We can demonstrate it. We can go to companies that are processing hundreds of patents a year and say, "We can absolutely do a better job than that big-name law firm." We can demonstrate it. To actually prove it, we've actually taken some of the patent applications that are public and examined them and showed them how bad the quality is that these other law firms are filing of their patents and how we can improve it. It really is disruptive.
When we're sitting down with new potential clients, we can actually demonstrate it to them, which again, is, I think, going to be very disruptive. We're going to complete a financing to scale up that marketing, bring in salespeople that can make it plainly obvious to the client that they need to transition their business to PatentVest, and we think that a growing client base can get this to profitability fairly quickly on not a lot of capital. We think we can create a lot of value. We think we can attract great lawyers because great lawyers will have to be on a platform like this. We're super excited about it. We believe that the practice of law will never be the same, and we're going to be a leader in this segment.
I really want to thank the hard work that the team at PatentVest has done to get us there. It's been a concentrated two and a half years of hard work to get there, but we're there, and we're ready for scale, and it's an exciting time. eXoZymes, what did we see with eXoZymes? It was super simple. Everybody knew that synthetic biology was the future, being able to create natural products that synthetic chemistry could not create or could not be extracted from the natural products in any kind of economic way. There were companies like Ginkgo and others that went to multi-billion dollar valuations, Amyris, Zymergen. What they proved was they couldn't scale in a cell-based environment, which is through fermentation.
What we had seen from the scientists at UCLA when we spun it out was that taking a cell-free process with just enzymes, that this was promising and could be done. In fact, the team has now proven it and has proven that the manufacturing process can scale, and taken it beyond our first product, and now creating a whole pipeline of products. This has been a monumental accomplishment by the team at eXoZymes. While the market has not yet recognized it yet, I can tell you, being on the board, being there day-to-day, I can see that we have also, with AI, been able to rapidly scale the process of not only finding new compounds that we can make, but also getting them to manufacturing at a price that nobody thought would be possible before.
The company has shown not only scale-up, but also shown scale-up at an unprecedented cost, so that things that we would start off thinking, "Well, maybe we can make it for $3,500 a kilo," we can make it for now under $1,000 a kilo. That's really important when you're creating a nutritional supplement. People can't pay $5 a day to take a nutritional supplement. It's got to be effective, and it's also got to be cost-effective as well. Now we've been able to achieve that, not only with NCT, and we're now believing we can achieve it with other compounds as well that have great scientific validation, that we believe could sell hundreds of millions, if not billions of dollars of product going forward, and could be some of the biggest nutritional supplements ever launched.
There's a whole host of numerous compounds in the pipeline, and these nutraceutical companies and pharma companies need new compounds. If you're a nutraceutical company and you're great at marketing nutritional supplements, you need something that's proprietary that nobody else has, because you're not going to make any money selling vitamin D when there's 50 people selling vitamin D. You need new compounds that are proprietary, and eXoZymes can deliver that. Pharma, as you can see, is getting desperate as they're facing patent cliffs, and they're starting to buy companies for very large valuations that are very early in development. We are very confident that we can show them new compounds that have great scientific groundings underneath them or foundations underneath them that affect pathways that they know exist. We're super excited about our ability to sit down with them and actually get to partnerships.
Those partnerships are critical to getting these compounds to market, because we're in the business of discovery and manufacturing, not in the business of actually launching these products. Those partnerships will bring scale to those, and I think you'll see some announcements shortly of relationships that will start to show that these are going to be marketed by other companies. We believe these compounds can create billions of dollars of value, potential market value for eXoZymes and the partners. That's never really been possible in synthetic biology before, and you can never tell it from the stock price, but we do believe that it will get recognized. It is real. Anybody that wants to go visit the company, bring the most brilliant scientists you want to the company to go see in person, we encourage you to do it.
This is an extraordinary opportunity that we're very proud of. Lastly is Paulex Bio. Paulex, if you remember, we started the company with folks that we started Provention with, that was a big success for us. A company that pioneered treatment of type 1 diabetes or helping delay or prevent type 1 diabetes through a drug that people had a lot of question about, but it actually got approved, it worked, and the company got bought for $2.9 billion. We worked with them to license a new drug that we're super excited about that will effectively, hopefully, enable people to regrow beta cells to make insulin again. Whether it's a type 1 diabetic or a type 2 diabetic, obviously the market is huge. It also fits really where major drug companies are looking for things. It's a small molecule, so it's a pill.
It's not a biologic. It's very different than the road we had with Provention, which was a biologic, which was difficult to manufacture and difficult to dose as well. That enables what we say is asymmetric upside, where if this pill works, the kind of return to our investors, because of the promise and how it will fit with big pharma, is really potentially very huge. As I said, we worked with them to license that drug from Mount Sinai, and do a $19 million seed round. We're probably about two months behind on. We were looking at sort of September to dose our first patients in the clinical trial. It took a little bit longer, and it looks like December is when we'll start to dose the first patients for safety, which we think is a very big milestone.
We own a very nice piece of this company, and we have planned, we filed a registration statement confidentially. We do believe that the company would like to go public in the first half of next year, and we're working toward that process now. We hope to see that the company is public, as well as hitting the critical milestones of safety and potentially efficacy by showing that beta cells can be regrown. As I said, the first milestone is safety, and we hope to be able to start to show that here very soon. Because this drug in preclinical studies is potentiated by GLP-1, it actually dramatically increases the effectiveness of it, we think it's a natural to be partnered with the pharma companies that are battling it out in the GLP-1 space.
We know that they need to have something that is unique and differentiated, like this drug, to give them a seat at the table in this new space that is turning into a potentially $100 billion market, and growing over the next few years. For the first nine months, we had fee income of about $4.2 million. It is up from last year, so it ameliorated our burn a bit this past year. We kept costs relatively the same, and now, through spinning out and effectively funding PatentVest and Public Ventures separately, we can bring our cash utilization down significantly. Right now, we are working on those two financings and spinning those out and partnering those out, as I have discussed earlier, which dramatically extends our runway. We had about $8.3 million in operating cash.
We had some other deposits for clearing and things like that increased that cash position. Our goal is to reduce that operating spend so that we are not having to raise additional capital to extend our runway to get these things to a value inflection point. As the largest shareholder, I can tell you the last thing I want to see is dilution, and I want to make sure that we get these things to a value-creating point, and then distribute that value out to the shareholders as soon as humanly possible. Again, to reiterate, the structure was set up to do that. We are not going back on that promise. We want to deliver these assets out, and I think that we expect to have distributions in 2027 of those assets to the shareholders.
We are right now reviewing that with the board about how to do that, when to do that, but our goal is to deliver as much out to the shareholders in 2027 as possible. We hope to have some important updates on that shortly. While I am decidedly upbeat and I am very excited about what we have done in launching these four companies, we also have to manage risk. The risk is, we are still doing financings for companies like eXoZymes, Paulex, and we cannot control the markets around those. The timing of those transactions and financings are important, and we are working hard on that. We are in the midst of spending a lot of our time focused in that area.
The science, I think the science is now well-established at eXoZymes, and I think we will start, and the science is well-established with Paulex, but there are some critical milestones with both safety and efficacy for Paulex that we are going to see in the very short term that will impact dramatically the valuation of that company. We obviously have concentration.
These assets can be good and bad, but I think that we have four assets. If any one of them work out great, we believe that could create multiples of our current stock price. If you think about eXoZymes or Paulex or any of these going to significant valuations, it has a big levering aspect on our stock, being that we have just under 11 million shares outstanding. We are still very hopeful that at least one of them works out. If one of them works out, it could be great.
If all of them work out, it will be phenomenal. The markets for small public companies, I do not have to keep reiterating that. You guys know what that is like. We have seen a company like Buda Juice that we do not have a huge equity interest in, but we love the company, and they have done nothing but perform. They have crushed it. They just announced earnings this week.
Their revenues were up 60%. Earnings were up great. We are completely convinced that Fresh Juice is going to be in every major supermarket in the country, and they are going to be leading that charge. And yet the stock went down on unbelievable earnings. We cannot control that, but we are super proud of what they have done. They have done exactly what we expected them to do. What we did not expect was that people do not care right now. But we do not think that that will persist forever.
Again, we really love what our companies are doing. They have all been moving things forward very well. Even again, another company we do not have a huge equity position in, like HeartBeam, this thing is what appears to be super close to being approved for heart attack detection. Could save millions of lives, could be everywhere, yet the market is just worried about financing risk and is just worried that maybe they will not get there. And we have seen this before, and we have seen it where it gets dark like this. Today, I could not tell you that right now it seems like people are throwing in the towels on these things. And maybe it goes lower, I do not know, but I certainly do not think that these great companies are just going to be totally ignored forever.
The markets have been confounding for us and what have you, but again, I cannot control the markets, and we are very hopeful that we are near the bottom. And I think on execution, these business development partnerships are super important. I am working most of my time right now in making sure we find the right partner for Public Ventures. And Javier and team are doing a great job at PatentVest. They are at a legal tech conference right now. They are talking to a number of companies that are interested in partnering with PatentVest, as well as attorneys that want to join the bench and companies that are looking for a unique solution to prosecute IP. A lot of execution needs to be done there, and I know the team is working very hard after having built a great platform.
Also, with eXoZymes, we have got to get some deals done with marketing partners to sell these compounds that we are going to be putting into production shortly. And I think with Paulex, execution on the clinical trial and then ultimately probably partnerships with big pharma that are going to want to bring that to the global medical landscape.
With that, we have been in the business of turning ideas and what we think are valuable assets into enterprises. None of that has changed. We have got four very valuable enterprises in our mind, and we are excited to get these things to commercialization. It has not been easy. It is very tough. We are buckling down. We are scratching to get these things lifted, and we are, we think, close on several of them. We remain optimistic, albeit sanguine about the current environment that we are in.
With that, George, I will turn it over to you to handle questions.
Take some questions. Chris, you might want to pull them up as well. I want to make a comment that we are in the middle of a financing with eXoZymes under an S-1 that has been filed. I would have you take a look at that S-1. There is a lot of information in there. If you have not had a chance to look at the presentation that management has made here, there is a recording from NetRoadshow that I think we are going to try to put out to all of our shareholders and account holders tomorrow, and you can have an opportunity. A lot of the questions I have in the chat board are regarding eXoZymes and that presentation.
I just want to make sure that we are under this S-1 and this financing right now, so we really cannot do much as far as going over and above what is stated in the S-1. That said, Chris, one of the questions is on cannabinoids. Can you talk a little bit about that market and what you see as far as what eXoZymes could do in the cannabinoid market?
Cannabinoids are super interesting. We will see, I think, both at a federal level and state level, it has been constrained because cannabinoid development has been, I wouldn't say a dirty word, it is just been, I think, muddled. It has been held back from a nutritional supplement perspective, but from a pharmaceutical perspective, I think it was constrained as well, but I think it is starting to gain a lot of appeal because you have got the CB1 and CB2 receptors that are on so many of your cells in your body, and these compounds have been shown to do lots of things, whether it is deal with all kinds of medical conditions. I think the company has demonstrated that they have the only synbio platform that can actually manufacture these as drugs or as nutritional supplements.
We're pretty excited about it because there's so much scientific research that's already been done on cannabinoids, but a lot of it just couldn't be made, and we can. We're hoping that we can spin out a new company out of eXoZymes at some point to serve that market, because we see it as a multi-billion dollar market. There's one cannabinoid that's been approved that is doing over a billion in sales and got bought for about $7 billion. We think we can create multiples of those potentially. It's a super exciting platform potential amongst a lot of the other things that are being developed at eXoZymes.
Here's a question about the AI drug designing and the whole frontier of new drugs that AI is discovering. Where does eXoZymes fit in with these AI companies on that?
The great thing about these tools companies, whether it was PatentVest or now eXoZymes or even what we're doing at MDB, we have processes that when we would look at a company, to give you an example now, we would look at a new co, we would get into a data room of a company looking for financing, and it would take us months to complete diligence to see if we wanted to get behind it. In some cases, we're able to rule in or rule out in a day. It's shocking that we've been able to do that. It's the same at eXoZymes right now. What happened was eXoZymes has a toolkit of these enzymes. They understand how to manufacture enzymes, and they understand these pathways of how to make a drug using enzymes or make a compound using enzymes.
AI just supercharged it because they were able to now utilize much more data that they have to get to an answer quicker. Their ability to effectively prototype a new drug has gone from, in the old synthetic biology, taking years to do, they can do it in sometimes days. That's how powerful this is. It's going to have a massively profound impact on new drugs and treating disease that goes well beyond eXoZymes. But eXoZymes has a toolkit with known compounds and known pathways to be able to get there so fast, and that's what's exciting. I think that now that we've shown the ability to scale manufacturing, drug companies have to be interested in this. That's why I said we've got to get partnerships done with drug companies, because we have it now.
We have the ability to make compounds that they need to fill their pipeline with that you can't just go get from other people. We have a unique capability at eXoZymes that no other synbio company has. It's a super exciting time. We're going to hit on one of these drugs that's going to really open the sky for the company, I think. It's a very, very exciting time for eXoZymes.
From the pharmaceutical perspective, how long does it take to gin up some interest, whether the cannabinoids or a new molecule? For those that don't understand that pharmaceutical pathway, what would that look like, and where do you think that eXoZymes
Well, the good news is that we have the ability to manufacture small quantities quickly so they can be tested very quickly in animals.
Yeah.
Again, many of these compounds are not easy to make. Even the drug that Paulex is putting in the clinic, it's a small molecule, but it wasn't trivial to manufacture that drug. It actually took time to get clean manufacturing for that drug. We're going to be able to dramatically enhance that and get these things to the clinic quickly so we can test them preclinically, which then gives big pharma the confidence to put it into the clinic with humans quickly. I think the cycle can be much faster. We've seen some of these AI, let's call it drug discovery platforms, doing big deals with folks like Anthropic and others, and we think that that's totally possible for eXoZymes as well.
Question on the large position. We have a large position in all four of these, smaller in Buda and smaller in HeartBeam, but large in those four. Can you kind of describe what your thinking is on the distribution strategy, if you get to an inflection point, what you mean by that?
Well, I think that I am hoping that eXoZymes gets to an inflection point in 2027 so that it is already public, it would be very easy to distribute. Once it gets to that inflection point, they have got their financings done per se, then that is a good time to distribute. Hopefully, we are hoping that that all happens and we can make the distribution of those shares to the shareholders very soon. That is an easy one. The other ones are not public yet, so the idea of getting them public is important to us. We are talking about a way to get Public Ventures public in a partnership, and we are looking at that. We are also looking at PatentVest and potentially taking that public as well. If we do, then it is easy to distribute those assets.
Our first priority being that we are in the public venture business is to get these companies public.
Yeah.
That is the easiest way to-
Do you worry that if you do that early, it would put pressure on the stock? Is that why you'd look at them? You'd want them to be healthy trading volume, well-financed.
Yeah. eXoZymes is not trading much volume. It hasn't gotten that real pop yet based on commercialization or an inflection point. But when it does, we've had in the history when these things really hit, they trade millions of shares a day. So distributing out millions of shares is not going to negatively impact anything.
Right.
So
Paulex questions. The Paulex is going into, as you said, into people here later this year. Where is the confidence as far as that this drug on the data we have so far has a better probability of working than, say, a cancer drug? Do you have any kind of a feel for that, why you're confident that this might have a higher probability of actually showing some success in people?
Well, listen, it's been validated, this pathway. It basically enables, takes the brakes off producing beta cells. And it's been shown with human cells in animals, and that's a big thing. I mean, that's never been done with a drug ever, safely, that is. It was done with a drug unsafely, and it got pulled off the market. Or got pulled out of trials, I should say.
Yeah.
Yeah, we can do it safely, then that's the holy grail. I mean, it doesn't get any bigger than that in my mind. GLP-1s are big, but this will be, to me, a whole new category that we could be the leader in. And we're super close to knowing it. I mean, we're very close to knowing if it's safe, and we're also pretty darn close to knowing whether it grows beta cells too.
Right.
It's an exciting time. It's exciting, and it's a great time. I mean, if it works, it's going to be transformative.
We covered generally the questions here. I'm going to go ahead and put it back to you and go ahead and close out, Chris.
We covered all the questions already?
Yep.
All right.
Well, wait. I do not understand the last question, so I am going to go ahead and pass on it.
Okay. All right, guys. We are working our tails off to get these companies to an inflection point, get them to be super valuable companies, as we have done with a lot of our companies in the past. We are excited. We are also stressed as well. I mean, the market has not been kind to these companies and to us, but it does not change what we are doing. We are coming to work every day.
We are really excited about the prospects, and we just keep hammering away every day to get these companies to that level. We really appreciate you all sticking in there with us, joining a conference call, listening to us, participating in our offerings. It has been a really trying time for all of us, but nothing good is easy. We are still just as excited about all these companies and the mission that we undertook when we went public.
Thanks again.
Thank you, everybody. This concludes today's webinar.